Investigational drug · Phase 2
icovamenib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "icovamenib"
First trial start
2026
Mar 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "icovamenib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "icovamenib" as an intervention, largest first.
- Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic TargetsActive, not recruiting
Biomea Fusion Inc.Industry
NCT07502495 · 64 participants · Start Mar 27, 2026 · Primary completion Mar 2027
Drug: icovamenib 100mg; Placebo · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Canoga Park, California; Fountain Valley, California · 18 sites in all
Biomea Fusion Inc.Industry
NCT07502508 · 60 participants (planned) · Start Apr 30, 2026 · Primary completion Jun 2027
Drug: icovamenib 100 mg; Placebo · For: Type 2 Diabetes
Sites: Birmingham, Alabama; Canoga Park, California; Long Beach, California · 20 sites in all
Biomea Fusion Inc.Industry
NCT07254286 · 60 participants · Start Sep 11, 2025 · Primary completion Jan 14, 2026
Drug: Icovamenib; Icovamenib HPMC · For: Healthy Volunteer
Sites: Miami, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
Bruzzese A, Vigna E, Martino EA, et al. · Eur J Haematol 2026
- Clinical Integration of Menin Inhibitors in AML: Evolving Data and Therapeutic Perspectives.
Chen T, Kim G, Rahimi Y, et al. · Oncol Res 2026
- Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib.
Carraway HE, Nakitandwe J, Cacovean A, et al. · Haematologica 2025
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.